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Objective. Increasing evidence implicates serine
proteinases in pathologic tissue turnover. The aim of
this study was to assess the role of the transmembrane
serine proteinase matriptase in cartilage destruction in
osteoarthritis (OA).
Methods. Serine proteinase gene expression in
femoral head cartilage obtained from either patients
with hip OA or patients with fracture to the neck of the
femur (NOF) was assessed using a low-density array.
The effect of matriptase on collagen breakdown was
determined in cartilage degradation models, while the
effect on matrix metalloproteinase (MMP) expression
was analyzed by real-time polymerase chain reaction.
ProMMP processing was determined using sodium
dodecyl sulfate–polyacrylamide gel electrophoresis/N-
terminal sequencing, while its ability to activate
proteinase-activated receptor 2 (PAR-2) was determined
using a synovial perfusion assay in mice.
Results. Matriptase gene expression was signifi-
cantly elevated in OA cartilage compared with NOF
cartilage, and matriptase was immunolocalized to OA
chondrocytes. We showed that matriptase activated
proMMP-1 and processed proMMP-3 to its fully active
form. Exogenous matriptase significantly enhanced
cytokine-stimulated cartilage collagenolysis, while
matriptase alone caused significant collagenolysis from
OA cartilage, which was metalloproteinase-dependent.
Matriptase also induced MMP-1, MMP-3, and MMP-13
gene expression. Synovial perfusion data confirmed that
matriptase activates PAR-2, and we demonstrated that
matriptase-dependent enhancement of collagenolysis
from OA cartilage is blocked by PAR-2 inhibition.
Conclusion. Elevated matriptase expression in
OA and the ability of matriptase to activate selective
proMMPs as well as induce collagenase expression
make this serine proteinase a key initiator and inducer
of cartilage destruction in OA. We propose that the
indirect effects of matriptase are mediated by PAR-2,
and a more detailed understanding of these mecha-
nisms may highlight important new therapeutic targets
for OA treatment.
Metalloproteinases, especially matrix metallopro-
teinases (MMPs), are considered to be the most impor-
tant class of proteinase in terms of cartilage degradation,
because collectively they can degrade all components of
this complex extracellular matrix (ECM) (1). Indeed,
type II collagen is a major structural component of this
ECM, and collagenolysis is an essentially irreversible
step (2), making such proteolysis a major therapeutic
target (3). Collagens are remarkably resistant to prote-
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olysis, and relatively few enzymes are able to effect their
hydrolysis. MMP-1, MMP-8, and MMP-13 are “classic
collagenases,” with MMP-1 and MMP-13 most strongly
linked to cartilage degradation in rheumatoid arthritis
(RA) and osteoarthritis (OA) (3).
Articular cartilage provides a friction-free artic-
ulating joint surface and is an unusual tissue, because it
is only sparsely populated by a single cell type, the
chondrocyte. These cells are responsible for ECM de-
velopment and maintenance and are subject to a variety
of stimuli in both normal and pathophysiologic settings.
During disease states, abnormal stimuli, including ab-
normal loading, as well as proinflammatory stimuli such
as interleukin-1 (IL-1) and tumor necrosis factor 
(TNF) (4,5) prevail, which leads to uncontrolled ECM
turnover. These factors are known to be present in both
RA and OA, and we have demonstrated that the IL-6
family cytokines IL-6 and oncostatin M (OSM) mark-
edly exacerbate the catabolic potential of these media-
tors. Indeed, we have demonstrated synergistic, MMP-
dependent cartilage catabolism in vitro and in vivo
(6–9), and we and other investigators have used IL-1
plus OSM as a potent stimulus for inducing cartilage
destruction.
In the last few years, the full repertoire of human
proteinases, termed the degradome, has been defined
(10). Studies revealed many new serine proteinases, such
that there are almost as many as there are metallopro-
teinases. Evidence is now emerging that serine protein-
ases have many diverse roles in both normal and patho-
logic scenarios, and this also applies to destructive joint
diseases (for review, see ref. 11). We have previously
reported that serine proteinase inhibition with inhibitors
of urokinase plasminogen activator (uPA) (12) and
furin-like enzymes (13) can block cytokine-stimulated
collagenolysis. Our findings have consistently supported
the notion that serine proteinase pathways activate
latent, inactive proMMPs (12–14); such evidence sug-
gests that proteolytic networks exist in resorbing carti-
lage. These findings therefore make serine proteinases a
potential therapeutic target, although the identity of
specific enzymes remains elusive.
In OA, collagenolysis initially occurs around the
chondrocytes (15), implicating proteinases associated
with the cell surface. Using a serine proteinase–active
site-specific probe, we previously identified fibroblast
activation protein  (FAP), an integral membrane
serine proteinase. Of note, FAP expression is signifi-
cantly higher in OA cartilage compared with phenotyp-
ically normal articular cartilage (16,17), although the
role of this transmembrane dipeptidylpeptidase has not
yet been deduced. We have now extended our initial
study (16) and performed a screen of OA and normal
cartilage for serine proteinase gene expression in order
to identify potentially important candidates in the pro-
posed serine proteinase pathways. This screening high-
lighted matriptase 1 (hereafter referred to as
matriptase), one of 20 type II transmembrane serine
proteases (TTSPs) (for review, see ref. 18). The biologic
functions of the matriptase subfamily, which includes
matriptases 1, 2, and 3 as well as polyserase 1, are poorly
defined, although matriptase is known to be important
in a variety of processes, including embryonic develop-
ment and tumor invasion (18). This enzyme is not
expressed in normal cartilage (19), while its activation
and activity are regulated by the endogenous transmem-
brane Kunitz-type serine proteinase inhibitors hepato-
cyte growth factor activator inhibitor type 1 (HAI-1) and
HAI-2 (20).
We propose that matriptase is an important
mediator of catabolic events in diseased cartilage. Spe-
cifically, we demonstrate that the expression of
matriptase and HAI-1 is increased in OA cartilage, and
that the addition of matriptase to cartilage enhances
collagenolysis and induces the expression of both
MMP-1 and MMP-3. We show that matriptase is an
activator of proMMP-1 and proMMP-3 as well as
proteinase-activated receptor 2 (PAR-2). Thus,
matriptase has direct and indirect roles that drive carti-
lage breakdown in OA.
MATERIALS AND METHODS
Materials. All chemicals of the highest purity available
were obtained from Sigma unless stated otherwise. All cyto-
kines and proteins used were recombinant human. IL-1 was a
generous gift from Dr. Keith Ray (GlaxoSmithKline). OSM
was produced in-house (21). ProMMP-3‚C was a generous
gift from Dr. Rob Visse (Kennedy Institute, London, UK),
while human matriptase (catalytic domain, residues 596–855)
was prepared as previously described (22), as were proMMP-1
and proMMP-13 (23). A matriptase antibody (catalog no.
IM1014), GM6001, and its negative control and the FS-6
substrate were obtained from Calbiochem. A PAR-2 antibody
(SAM11, azide-free) was purchased from Santa Cruz Biotech-
nology. ENMD-1068 (24) was obtained from Enzo Life Sci-
ences. The cathepsin K inhibitor L-873724 was a kind gift from
Dr. Cameron Black (Merck Frosst).
Animals. Experiments were performed on adult wild-
type (PAR-2/) C57BL/6J mice (body weight 25–30 gm),
which were housed in standard cages with food and water
available ad libitum, with maintenance of a thermoneutral
environment. PAR-2–deficient (PAR-2/) mice were genet-
ically modified as described previously (25) and were main-
tained under the same conditions used for the wild-type mice.
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All procedures were performed in accordance with current UK
Home Office regulations. OA in C57BL/6J mice was induced
following surgical destabilization of the medial meniscus by
sectioning of the medial meniscotibial ligament; this results in
medial and posterior rotation of the medial meniscus, leading
to a mild form of OA (26). Sham operations were performed
in a subset of mice. The mice remained housed under the same
conditions for 4 weeks, after which the knee joints were
harvested for histologic examination.
Cartilage degradation assays. Bovine nasal septum
cartilage (obtained from a local abattoir) was dissected into
2  2  2–mm discs, plated into 24-well tissue culture plates
(3 discs/well; n  4) in serum-free medium, and incubated for
14 days in the presence of IL-1 with or without OSM (with or
without matriptase), changing the medium after 7 days, as
previously described (27). Cartilage remaining on day 14 was
digested with papain (27), and all samples were stored at
20°C until assayed. The viability of cartilage explants was
assessed by screening for adenylate kinase (AK) production
using the ToxiLight BioAssay Kit (Lonza). No increase in AK
levels with any of the treatments, including inhibitors, was
observed (data not shown).
Macroscopically normal articular cartilage was ob-
tained from patients with hip OA or from patients with
fracture of the femur neck who had no history of OA and were
undergoing total joint replacement surgery in hospitals in
either Newcastle or Norwich. The cartilage specimens were
prepared and treated as described above for bovine cartilage.
Cartilage samples were pretreated for 72 hours with PAR-2
inhibitors to allow efficient tissue penetration prior to stimu-
lation. All subjects gave informed consent, and the study was
performed with ethics committee approval.
Collagen and collagenolytic activity assays. Hy-
droxyproline measurements (28) were used as an estimate of
cartilage collagen, and the cumulative release was calculated
and expressed as a percentage of the total for each well (29).
Collagenolytic activity present in the culture media from
cartilage explants was determined using a diffuse fibril assay
with 3H-acetylated collagen, as previously described, where 1
unit of collagenase activity degrades 1 g of collagen per
minute at 37°C (30).
RNA extraction from cartilage. Total RNA from hip
cartilage samples was prepared as previously described (31);
cartilage specimens obtained from patients with fracture of the
femur neck were phenotypically normal and lesion-free. For
experiments in which human OA cartilage was cultured prior
to RNA isolation, RNA was prepared as previously reported
(16).
Real-time polymerase chain reaction (PCR) of relative
messenger RNA (mRNA) levels. For TaqMan and SYBR
Green PCRs, mRNA levels for each gene were obtained from
standard curves and corrected using 18S ribosomal RNA
levels. Cycling conditions (7900HT system; Applied Biosys-
tems) for the SYBR Green PCR (using TaKaRa SYBR Ex Taq
premix; Lonza) were 95°C for 10 seconds, then 40 cycles at
95°C for 5 seconds, then 60°C for 30 seconds, followed by a
standard dissociation curve analysis. Cycling conditions for the
TaqMan PCR (JumpStart Taq ReadyMix; Sigma) were 2
minutes at 50°C, 10 minutes at 95°C, then 40 cycles of 15
seconds at 95°C and 1 minute at 60°C. The human primer/
probe sequences used for the TaqMan PCR have been previ-
ously described (32).
ProMMP activation assays. Human recombinant and
titered matriptase (catalytic domain) was incubated with equal
volumes of either proMMP-1 (1:5 molar ratio) or proMMP-
3‚C (1:15 molar ratio) at 37°C in a 50-l final volume.
Working dilutions (25 l) of each enzyme were prepared using
25 mM sodium cacodylate, 10 mM CaCl2, 0.05% (weight/
volume) Brij-35, and 0.02% (w/v) sodium azide, pH 8.0.
Enzyme stocks were stored in the following: for matriptase, 50
mM Tris HCl, pH 9.0, 10% (v/v) glycerol, 1 mM
-mercaptoethanol, 0.4M NaCl; for proMMP-1, 20 mM Tris
HCl, pH 7.2, 5 mM CaCl2, 0.05% (w/v) sodium azide, 0.01%
(w/v) Brij-35, 0.5M NaCl; for proMMP-3, 50 mM Tris HCl, pH
7.5, 0.15M NaCl, 10 mM CaCl2, 0.02% (w/v) sodium azide,
0.05% (w/v) Brij-35, 10% (v/v) glycerol. Equal aliquots (8 l)
were removed at time points up to 24 hours and snap-frozen
until being resolved on 10% sodium dodecyl sulfate (SDS)–
polyacrylamide gels. For visualization, proteins were silver
stained. For sequence determination, incubations were per-
formed with or without GM6001 (50 M final concentration),
proteins were transferred to polyvinylidene fluoride mem-
brane, and bands of interest were excised after being stained
briefly with 0.1% (w/v) Coomassie Blue R-250 and subjected to
amino-terminal sequencing and/or mass spectrometry.
Substrate assays. Enzymatic assays of MMP activity
were performed in 0.1M Tris HCl, pH 7.5, 0.1M NaCl, 10 mM
CaCl2, 0.05% (w/v) Brij-35, 0.1% polyethylene glycol 6000.
Enzyme activity was monitored by measurement of the in-
crease in fluorescence (excitation 324 nm, emission 400 nm)
from 5 M Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2
(FS-6) at 37°C in an LS-50B fluorometer with microplate
accessory reader (PerkinElmer). Matriptase activity was con-
firmed using 25 M Boc-Gln-Ala-Arg-AMC (excitation 360
nm, emission 460 nm) in 0.1M Tris HCl, pH 9.0, 500 g/ml
bovine serum albumin, 0.01% (w/v) Brij-35.
Immunohistochemical analysis. For human cartilage,
tissue was frozen in ice-cold isopentane. Serial cryostat sec-
tions (10 m) on 3-aminopropyltriethoxysilane–coated (2%)
slides were prepared and immunostained as previously de-
scribed (23). Normal rabbit serum (1.5%) was used for block-
ing (10 minutes), and sections were incubated with anti-
matriptase antibody (1:1,000 dilution) for 90 minutes at room
temperature. Washed sections were then incubated with bio-
tinylated secondary antibody (rabbit anti-sheep IgG, diluted
50-fold in phosphate buffered saline [PBS] according to the
Vectastain kit instructions) in 1.5% rabbit serum in PBS for 30
minutes, followed by incubation with avidin–biotin complex for
30 minutes using Vectastain kit PK-6105 (Vector) according to
the manufacturer’s instructions. Decalcified murine knee joints
were embedded in paraffin wax, and, subsequently, sections (6
m) were deparaffinized, rehydrated, and stained with SAM11
antibody at 1 g/ml, using ARK (Animal Research Kit)
Peroxidase (Dako) according to the manufacturer’s instruc-
tions. Signal development was achieved with diaminobenzidine
tetrahydrochloride (Dako), following the manufacturer’s pro-
tocol. Images were captured using a 3-CCD color video camera
(JVC).
PAR-2 activation assay. Synovial perfusion was mea-
sured from the exposed medial aspect of the knee joint
capsules of parallel groups of wild-type and PAR-2/ mice,
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using high-resolution laser Doppler imaging (Moor Instru-
ments) as previously described (33). A series of scans were
obtained immediately following topical application of saline
vehicle, and once a stable baseline was achieved, a further
series of scans was obtained immediately after topical admin-
istration of matriptase. Images were later analyzed by dedi-
cated software to obtain median flux values over the knee joint
region. Vascular perfusion responses (in arbitrary perfusion
units) are presented as the percentage change from baseline.
The carotid artery was cannulated to allow blood pressure
monitoring.
Statistical analysis. Significant differences between
patient groups were determined using a Mann-Whitney
2-tailed U test. Standard TaqMan experiments were per-
formed at least in triplicate for a minimum of 3 separate
samples, with data analyzed using Student’s 2-tailed t-test.
Cartilage experiments were performed in quadruplicate for 3
different cartilage specimens, and significance was assessed
using analysis of variance (ANOVA) with a post hoc Bonfer-
roni multiple comparison test, using commercial software
(SPSS, v15.0). Blood flow measurement data were similarly
assessed by ANOVA. For clarity, only selected comparisons
are presented in some figures.
RESULTS
Elevated matriptase gene expression in OA tis-
sue. Analyses of total RNA from OA joint tissue and
normal joint tissue obtained from patients with femur
neck fracture revealed a statistically significant increase
in matriptase (ST14) gene expression in OA cartilage
(P  0.0039) (Figure 1A). In a separate experiment,
HAI-1 gene expression, but not HAI-2 gene expression,
was also significantly elevated (P  0.0039) in OA
cartilage (Figure 1B). The increase in matriptase gene
expression was reflected in detectable matriptase pro-
tein in several OA cartilage specimens (Figure 1C,
panels i–iii); PAR-2 was also detected in OA cartilage
(Figure 1C, panel iv).
Of the TTSP genes assessed, none other than
matriptase was up-regulated in OA cartilage, although
both HPN (hepsin; P  0.00006) and TMPRSS4 (MT-
SP2; P  0.00002) were markedly suppressed in OA
cartilage compared with normal cartilage (Figure 1A).
Figure 1. A and B, Elevated matriptase expression in osteoarthritis (OA) cartilage. Gene expression levels of several membrane proteinases (A) or
hepatocyte growth factor activator inhibitor type 1 (HAI-1) and HAI-2 (B) (analyzed in a separate set of samples, where n  12 for both OA and
neck of femur fracture [NOF]) were assessed in hip cartilage obtained from patients with OA (n  13) or in normal control cartilage obtained from
patients with NOF (n  12). Levels were determined as described in Materials and Methods and normalized to the level of 18S ribosomal RNA.
Since all primer/probe combinations amplify with essentially equal efficiencies, gene expression levels are directly comparable within each separate
set of samples. All detectable data points are shown; horizontal lines show the means. NS  not significant.   P  0.01;   P  0.001, OA
versus NOF, by Mann-Whitney 2-tailed U test. C, Detection of matriptase and proteinase-activated receptor 2 (PAR-2) in human OA cartilage.
Specimens were embedded in OCT compound, and 10-m sections were obtained using a cryostat. Matriptase was detected in 3 separate cartilage
samples using rabbit antimatriptase polyclonal antibody (panels i–iii), and PAR-2 was detected using SAM11 monoclonal antibody (panel iv). Panels
iii and iv show the same sample. Boxed area in panel i shows a higher-magnification view. Bars  100 m in panels i and ii and 50 m in panels
iii and iv.
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Figure 2. Cleavage sites in the propeptide regions of matrix metalloproteinase 1
(MMP-1) and MMP-3 of matriptase. Recombinant human proMMP-1 or proMMP-
3C was incubated with recombinant human matriptase (molar ratios 1:5 and 1:15,
respectively) for various lengths of time. A and B, Products generated from
proMMP-1 (A) and proMMP-3C (B) were resolved by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis. C, Mass spectrometry and N-terminal sequence
analyses were also performed on the 1–4-hour incubations. The data presented
include several known cleavage sites within the propeptide regions (shown in italics);
residue numbering is for the proform (for review, see ref. 35). Boxed areas show the
“bait” region, and the cysteine-switch regions are underlined. Cleavage sites marked
with upward-pointing closed arrows are for matriptase (plus GM6001); open arrows
mark sites that are matriptase-generated in the absence of GM6001. Pk  plasma
kallikrein; Tp  trypsin; Ct  chymotrypsin; He  human neutrophil elastase.
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These TaqMan Low Density Array data for cartilage
were validated by the significantly elevated expression of
FAP expression (P  0.0004), as has been demon-
strated previously (16,17). Furthermore, significant
elevations of several other serine proteinase genes were
detected, including high-temperature requirement A1
peptidase (HtrA1), PRSS23 (SPUVE), CFD and CFI
(complement factors D and I), and PCSK6 (proprotein
convertase 6), while PCSK1 (proprotein convertase 1)
and CFB (complement factor B) were significantly
down-regulated in OA cartilage (see Supplementary
Figure 1 and Supplementary Table 1, available on the
Arthritis & Rheumatism Web site at http://www3.
interscience.wiley.com/journal/76509746/home).
Matriptase-induced activation of proMMP-1.
Because matriptase is a known activator of proMMP-3
(34), we assessed its ability to activate the proforms of
the 2 major collagenolytic MMPs relevant to cartilage
collagenolysis. SDS–polymerase gel electrophoresis re-
vealed that matriptase failed to process proMMP-13
(results not shown) but did process proMMP-1, albeit at
a slower rate than for proMMP-3 (Figures 2A and B).
Mass spectrometry and amino-terminal sequence analy-
sis of the processed proMMPs revealed cleavage at
Arg74–Cys75 (cysteine-switch region) and at Arg35–
Arg36 (bait region) for MMP-3 in the presence of
GM6001 (Figure 2C). For proMMP-1, cleavage at
Thr64–Leu65 occurred in the absence of GM6001,
reflecting the presence of some active MMP-1 in the
preparation. Matriptase generated the [Val82]MMP-1
mature form irrespective of the presence of GM6001.
Full-length mature MMP-3 ([Phe83]MMP-3) was gen-
erated in the absence of GM6001, while inclusion
of this MMP inhibitor generated [Thr85]MMP-3 (Fig-
ure 2C).
Enhancement of IL-1 plus OSM–mediated carti-
lage collagenolysis by matriptase activity. Having dem-
onstrated that matriptase is an activator of both
proMMP-1 and proMMP-3, we hypothesized that the
exogenous addition of active matriptase to stimulated
cartilage would enhance collagenolysis. An ex vivo
model of cartilage degradation confirmed that on day 7,
a time point when little or no collagen release is typically
observed (29), significant levels of hydroxyproline (a
measure of collagen) were detected in the culture super-
natants. Furthermore, even with a low dose of IL-1 plus
OSM, matriptase (100 nM) still significantly enhanced
the release by day 14 (Figure 3). When collagenolysis
was evident at day 7, active collagenase was also de-
tected (results not shown).
Matriptase-enhanced OA cartilage collagenoly-
sis and collagenase gene expression in the absence of an
inflammatory stimulus. Although our data confirmed a
potential role for matriptase in cytokine-stimulated car-
Figure 3. Enhanced cytokine-induced cartilage collagenolysis by matriptase. Bovine cartilage explants were incubated with
interleukin-1 (IL-1) plus oncostatin M (OSM) with or without matriptase (100 nM unless indicated otherwise) for 14 days, with
fresh medium, cytokines, and reagents used on day 7, as appropriate. The concentrations of IL-1 plus OSM used are as follows:
high (H; 1 ng/ml plus 10 ng/ml), medium (M; 0.6 ng/ml plus 6 ng/ml), and low (L; 0.25 ng/ml plus 2.5 ng/ml). Collagen release
by day 7 (open bars) and cumulative day-14 release (closed bars) were determined by hydroxyproline measurement and
expressed as a percentage of the total for each treatment. Bars show the mean and SD results from at least 3 separate
experiments (n  4 samples).   P  0.001, IL-1 plus OSM plus matriptase versus IL-1 plus OSM.
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tilage, previous experiments with matriptase-treated bo-
vine explants failed to demonstrate any collagenolysis
(see Figure 3). However, assessment of the effect of
exogenous matriptase on human OA cartilage resulted
in the striking observation that matriptase alone induced
significant collagenolysis that was sensitive to the met-
alloproteinase inhibitor GM6001 but neither its negative
control nor a cathepsin K inhibitor (Figure 4A). Similar
results were observed when IL-1 plus OSM was also
included, except slightly more collagenolysis was ob-
served (Figure 4B). We also demonstrated significant
glycosaminoglycan release from OA cartilage following
matriptase treatment compared with control (results not
shown).
The finding that matriptase alone caused signifi-
cant collagenolysis, and that this was most likely medi-
ated by MMP, led us to hypothesize that the action of
matriptase on OA cartilage led to new collagenase gene
expression. Culture of human OA cartilage explants with
matriptase for 7 days revealed a significant increase in
the expression of both MMP-1 and MMP-3 mRNA,
while expression of MMP-13 mRNA was also increased,
although the difference was not statistically significant
(Figure 4C). All 3 MMP genes were detectable (Ct value
ranges for untreated human cartilage, 37.9–21.2; for
treated cartilage, 33.5–20.2). No increases in MMP-14
were seen, while di-isopropyl phosphorofluoridate–
treated matriptase failed to induce any MMP expression
(results not shown).
Expression of PAR-2, an in vivo substrate of
matriptase, in OA cartilage. To confirm the ability of
recombinant matriptase to act as an in vivo activator of
PAR-2, we assessed blood perfusion in murine joints
following topical administration of matriptase. This
demonstrated a rapid and significantly greater (P 
0.0001 by two-way ANOVA) increase in synovial perfu-
sion in PAR-2/ (wild-type) mice compared with their
PAR-2–deficient (PAR-2/) littermates (Figures 5A–
C). Arterial blood pressure was not significantly affected
by matriptase administration (mean  SD 1.1  0.3%
increase). Immunohistochemical analysis of murine
knee joints confirmed the presence of chondrocyte
PAR-2 and also revealed matriptase expression in chon-
drocytes from the OA model (destabilization of the
medial meniscus), but not in sham-operated mice (Fig-
ure 5D). Indeed, matriptase was detectable only at the
medial aspect of the joint, corresponding to where the
OA pathology associated with this model occurs.
Matriptase-enhanced OA cartilage collagenoly-
sis via PAR-2. Because we had demonstrated an indirect
role for matriptase in driving cartilage degradation,
Figure 4. Enhanced osteoarthritis (OA) cartilage collagenolysis by
matriptase. A and B, Human OA cartilage explants were incubated
with control medium with or without matriptase (100 nM), with or
without IL-1 plus OSM (1 ng/ml plus 10 ng/ml), and with or without
GM6001 (or its negative control; both 10 M) or L-873724 (10 nM) for 7
days. The collagen release by day 7 and cumulative release by day 14 were
determined by hydroxyproline measurement and expressed as a percent-
age of the total for each treatment. A, Matriptase as prime stimulus. B,
Matriptase plus IL-1 plus OSM as prime stimulus. Bars show the mean
and SD results from at least 3 separate experiments (n  4 samples). C,
RNA isolated from the day-7 cartilage was subjected to real-time poly-
merase chain reaction for matrix metalloproteinase (MMP) gene expres-
sion. The data were normalized to 18S ribosomal RNA, and the results
(representative of 3 separate experiments) are the mean and SEM fold
induction compared with basal (n  4).   P  0.05;   P  0.01
versus basal, by analysis of variance (ANOVA);   P  0.001 versus
GM6001-negative control, by ANOVA. See Figure 3 for other definitions.
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we next hypothesized that matriptase mediated this
effect by activating PAR-2. We (36) and other investi-
gators (37) have shown that PAR-2 is a target of
matriptase, and 2 different PAR-2 inhibitors (SAM11
and ENMD-1068) both significantly prevented collagen-
olysis (Figure 6).
DISCUSSION
The burgeoning field of degradomics has enabled
research into aberrant proteolysis to make important
new discoveries. Cartilage disassembly during disease
involves multiple proteinase cascades that are likely to
be interdependent. We and other investigators have
reported that human OA cartilage is highly resistant to
proinflammatory stimuli despite increased expression of
collagenolytic MMPs; the reasons for this resistance are
unclear, although failure to activate latent procollage-
nases could be an explanation (29). Our previous data
strongly implicate serine proteinases with roles in patho-
logic cartilage turnover, especially procollagenase acti-
vation (12–14), but identifying specific enzymes has been
difficult.
Our current screen of 100 serine proteinases in
OA cartilage samples and phenotypically normal carti-
lage samples (obtained from patients with a femur neck
fracture) corroborated previous findings of significantly
elevated expression of several serine proteinases in OA
cartilage, albeit with differing degrees of significance, as
recently outlined (17). The elevated expression of FAP
observed in the present study corroborates previous
independent reports (16,17); these data suggest that this
post–prolyl peptidase, known to modify chemokines and
bioactive peptides (38), may have a protective role in
OA. Another up-regulated enzyme to be confirmed was
HtrA1 (17), which further implicates this proteinase in
catabolic ECM turnover, because treatment of synovial
fibroblasts with HtrA1 or HtrA1-generated fibronectin
fragments induces MMP-1 and MMP-3 expression (39).
Of the TTSPs screened, most were unaltered and
expressed at very low levels. However, the expression of
Figure 5. Expression of proteinase-activated receptor 2 (PAR-2), an in vivo substrate of matriptase, in an osteoarthritis model. A and B, Sequential
laser Doppler images showing vasodilatation within 1–2 minutes after topical administration of 10 g of recombinant matriptase (arrows) to
PAR-2/mice (A) or PAR-2/mice (B). Perfusion was measured in arbitrary flux units and color coded (dark blue lowest, dark red highest).
C, Mean and SEM percentage change in perfusion (n  3). D, Consecutive knee joint sections (6 m) from C57BL/6J mice that underwent either
destabilization of the medial meniscus (DMM) surgery or sham operations, stained for matriptase or PAR-2. Results are representative of at least
3 separate mice. Bars  20 m.
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one TTSP gene was significantly elevated in OA carti-
lage compared with normal cartilage, namely,
matriptase, which is widely expressed in various cancers.
A failure to suppress matriptase expression during dis-
ease may therefore have catabolic-related implications
for cartilage. Several putative substrates of matriptase
have been identified, including pro–hepatocyte growth
factor and the serine proteinases pro–urokinase plas-
minogen activator (pro-uPA) and prostasin (40), with a
major role as initiators of serine proteinase cascades. We
have proposed that such cascades are important in
cartilage degradation (11–13); this initiator hypothesis is
further supported in that matriptase activation is auto-
catalytic (41), which is uncommon for a latent serine
proteinase. In fact, matriptase activation is a complex
process requiring its cognate inhibitor, HAI-1, which
enables appropriate trafficking to the cell surface (42).
This process therefore directs matriptase activity to the
cell surface while providing a means of regulating this
activity. In turn, this suggests that increased matriptase
expression and subsequent activity would result only
with a concomitant increase in HAI-1 expression. We
found this situation to exist in OA cartilage, with the
data strongly implying elevated matriptase activity in
OA.
Some of the potential consequences of
matriptase activity in cartilage are well aligned with our
previous data (12–14). MMP-3 is a key activator of
procollagenases (43,44), and we confirm that matriptase
processes proMMP-3 (34) to a fully active enzyme
following intermediate cleavage within the bait region
(Arg–Arg bond), consistent with its preference for posi-
tion P1 (37). This intermediate species generates a fully
active MMP-3 with an N-terminal Phe. Interestingly,
inclusion of an MMP inhibitor revealed cleavage at the
Arg–Cys bond within the cysteine-switch regions for the
MMP-1 and MMP-3 proforms; this same bond is cleaved
in MMP-7 and MMP-8 by trypsin and in MMP-13 by
plasmin (for review, see ref. 35). This presumably re-
sults in the loss of MMP latency, because in the absence
of MMP activity, matriptase ultimately processed
proMMP-1 and proMMP-3 to less active forms similar
to those generated by chymase and trypsin, respectively
(35). However, MMP-3 is typically coordinately ex-
pressed with MMP-1 and MMP-13 (45) such that in vivo,
matriptase action on proMMP-3 will generate an
MMP-3 enzyme capable of processing collagenolytic
MMPs to their most active forms (35). This is evidenced
by the enhanced collagenolysis on day 7 when cytokine
stimulation alone failed to promote such collagenolysis
(29); this therefore provides a mechanism that maxi-
mizes the degradative potential of the procollagenase
pool and one that preferentially localizes this activity at
the cell surface to effect pericellular collagenolysis.
Matriptase also activates pro-uPA (37), which
generates active plasmin from plasminogen. Although
we confirmed the absence of plasminogen expression in
OA cartilage (data not shown), this enzyme is expressed
in synovial tissue. Both MMP-3 and plasmin activate
procollagenases to expedite collagenolysis in resorbing
cartilage (12,46), and plasmin has several other roles
that contribute to ECM remodeling (11). We have
proposed that procollagenase activation represents a key
and rate-limiting step in cartilage collagenolysis, and
confirmation that matriptase activates proMMP-1 as
well as expedites collagenolysis from proinflammatory
cytokine–stimulated cartilage (with a concomitant in-
crease in detectable active collagenase) further supports
the notion that matriptase could be a major player in
such processes. We have also shown reduced collag-
enolysis from stimulated cartilage following the addition
of anti–thrombin III or PA inhibitor 1 (Milner JM,
Rowan AD: unpublished observations); these serpins
inhibit matriptase (47), albeit not specifically.
Figure 6. Proteinase-activated receptor 2 (PAR-2)–mediated
matriptase-enhanced osteoarthritis (OA) cartilage collagenolysis. Hu-
man OA cartilage explants were incubated with control medium with
or without either a neutralizing antibody to PAR-2 (SAM11) at 400
ng/ml final concentration or the same antibody that had been previ-
ously heat-denatured (SAM11d), or ENMD-1068 at 10 mM final
concentration for 72 hours. Subsequently, matriptase (100 nM) was
added such that the SAM11 antibody and ENMD-1068 remained at
final concentrations of 200 ng/ml and 5 mM, respectively, for 7 days.
Collagen release was then determined by hydroxyproline measurement
and expressed as a percentage of the total for each treatment. Bars
show the mean and SD results from 3 separate experiments (n  4
samples). †††  P 0.001 versus control;   P  0.001 versus
matriptase alone, by analysis of variance.
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Historically, human OA cartilage explants are
highly resistant to proteolysis, even following stimulation
with highly catabolic cytokine combinations such as IL-1
plus OSM. Indeed, only 25% of cartilage specimens
respond with typically very low collagen release (29).
The current study also failed to promote cytokine-
induced collagenolysis despite collagenase(s) induction
(data not shown). However, the most striking observa-
tion was that even in the absence of a proinflammatory
stimulus, matriptase induced significant collagenolysis
fromOA cartilage, which was entirely metalloproteinase-
dependent. Inclusion of matriptase with a proinflamma-
tory stimulus (IL-1 plus OSM) promoted slightly more
collagenolysis, presumably via the activation of cytokine-
induced proMMPs. This new MMP expression occurred
as a consequence of matriptase action on OA cartilage
that was significant for MMP-1 and MMP-3. Matriptase
activity would subsequently activate secreted proMMPs,
although we cannot exclude the possibility of concomi-
tant initiation of another activation cascade.
These highly novel observations suggest that
matriptase may mediate its effect via a cell surface
receptor specifically expressed in OA cartilage, because
treatment of healthy bovine or nondiseased human
cartilage with matriptase failed to promote collagenoly-
sis (data not shown). Matriptase is a known activator of
PAR-2 (36,37); this mechanism involves the proteolytic
release of a tethered ligand, which can be mimicked by
use of a PAR-2–activating peptide [48]). We confirmed
this mechanism in vivo using wild-type and PAR-2–
deficient mice in synovial perfusion assays, as previously
performed for -tryptase (33). The small amount of
vasodilatation in the PAR-2–deficient mice may indicate
that matriptase has a minor non–PAR-2–mediated ef-
fect. PAR-2 expression is significantly elevated in OA
cartilage compared with normal cartilage (49,50), and
synthetic activation of PAR-2 in OA cartilage induces
both MMP-1 and MMP-13 (49), which is consistent with
our observations using matriptase.
We have previously shown that the PAR-2 antag-
onist, ENMD-1068, is effective at inhibiting PAR-2
when activated proteolytically (trypsin) or via a PAR-2–
activating peptide (51). In the current study, PAR-2
inhibition with a neutralizing antibody (SAM11) or
ENMD-1068 effectively blocked matriptase-induced col-
lagenolysis, thus confirming PAR-2 as a target for
matriptase in OA cartilage. We have previously impli-
cated PAR-2 as having a role in RA, because it is highly
expressed in rheumatoid synovium, and the spontaneous
synovial expression of both IL-1 and TNF is markedly
reduced following PAR-2 antagonism (24). Further-
more, chondrocyte PAR-2 expression has been shown to
be increased following stimulation with IL-1 or TNF,
both of which are proinflammatory cytokines implicated
in OA (4,5).
The expression of various cell surface receptors is
altered in OA (e.g., some Toll-like receptors [TLRs]
[52]), which may well be a consequence of inflammation
(IL-1, TNF) and/or aberrant mechanical load. This
altered phenotype may then increase susceptibility to
further stimuli for ECM degradation. Interestingly, al-
though PAR-2 was detectable in chondrocytes from
both sham-operated and OA joints, matriptase was con-
sistently detectable only in the latter. Moreover,
matriptase was detected only in locations where PAR-2
was also present. This suggests that PAR-2 may act as a
sentinel for proteinase-mediated injury signals, such as
matriptase expression due to joint destabilization, lead-
ing to PAR-2 activation and signaling, resulting in
cartilage degradation. PAR-2 expression is also elevated
in OA subchondral bone, and PAR-2 activation in-
creases bone resorption (53). Taken together, these
findings clearly support a catabolic role for PAR-2 in
both RA and OA.
The ability of matriptase to activate key MMPs
makes it an important effector of cartilage degradation.
We recently highlighted the importance of serine pro-
teinases in cartilage breakdown (11) and propose
matriptase as a key initiator of proteinase cascades,
including MMPs, that collectively orchestrate ECM
turnover. Furthermore, matriptase activity in OA carti-
lage leads to the induction of collagenolytic MMPs, a
process we suggest occurs via PAR-2 activation.
These properties of matriptase offer a paradigm
for OA, in which an initial focal injury or inflammatory
event leads to localized, altered chondrocyte receptor
expression, which, when combined with matriptase ac-
tion, leads to PAR-2 activation and subsequent MMP
activation (e.g., MMP-1) at the cell surface; this then
facilitates pericellular collagenolysis within this focal
region of the cartilage. This could have direct implica-
tions, because MMP-1 is a known activator of PAR-1,
shown to be expressed in cartilage (54), leading to new
MMP expression (55). In the context of altered receptor
expression in OA cartilage, MMP-mediated proteolysis
of the ECM may also generate ligands for TLRs that
normally are not abundantly expressed (e.g., TLR-2)
(52). All or a combination of these mechanisms could
thus perpetuate cartilage degradation in the absence of
classic inflammatory cues, especially in OA. Periodic
recurrences of such events over time may also explain
the slower progression of OA compared with RA, a
1964 MILNER ET AL
disease that is characterized by more persistent inflam-
matory stimuli and synovial involvement.
In summary, we have shown that the TTSP
matriptase is expressed in OA cartilage, and that this
enzyme is both an inducer and activator of procollage-
nases. Therefore, matriptase is a highly attractive new
target for preventing pathologic cartilage breakdown.
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